Study to Assess the Efficacy and Safety of VX-210 in Subjects With Acute Traumatic Cervical Spinal Cord Injury
Recruiting in Palo Alto (17 mi)
+38 other locations
Age: Any Age
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2 & 3
Waitlist Available
Sponsor: Vertex Pharmaceuticals Incorporated
Prior Safety Data
Trial Summary
What is the purpose of this trial?
The purpose of this study is to determine the efficacy and safety of VX-210 in subjects with Acute Traumatic Cervical Spinal Cord Injury. Secondary objectives include the specific evaluation of the effects of VX-210 on neurological recovery and daily function after spinal cord injury.
Research Team
Eligibility Criteria
Inclusion Criteria
Screening UEMS score must be ≤16 points on each side.
AIS A subjects with a C4 motor level on both sides must have at least 1 point of motor activity between C5 and T1 on at least 1 side.
AIS B subjects with a C4 motor level on both sides must have at least 1 point of motor activity between C5 and C7 on at least 1 side.
See 3 more
Treatment Details
Interventions
- Placebo (Drug)
- VX-210 (Other)
Participant Groups
2Treatment groups
Experimental Treatment
Placebo Group
Group I: VX-210Experimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
NCT02669849Tampa, FL
NCT02669849Iowa City, IA
NCT02669849Austin, TX
NCT02669849Dallas, TX
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
Vertex Pharmaceuticals Incorporated
Lead Sponsor
Trials
267
Patients Recruited
36,100+